PMID- 31474855
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231013
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Ruthenium Chloride-Induced Oxidative Cyclization of Trans-Resveratrol to 
      (+/-)-epsilon-Viniferin and Antimicrobial and Antibiofilm Activity Against Streptococcus 
      pneumoniae.
PG  - 890
LID - 10.3389/fphar.2019.00890 [doi]
LID - 890
AB  - Polyphenol epsilon-viniferin (2) is a protective phytochemical found in several plant 
      families. Here, we report a simple and effective method for the synthesis of 
      (+/-)-epsilon-viniferin (2) as major product and (+/-)-(E)-omega-viniferin (3) as a minor 
      product. Synthesized viniferin compounds and standard viniferin were analyzed for 
      antibacterial and antibiofilm activity against Gram-positive bacteria 
      Streptococcus pneumoniae. The minimum inhibitory concentrations (MICs) of 
      (+/-)-epsilon-viniferin (2) and standard viniferin were 20 microm. However, the MICs of 
      (+/-)-(E)-omega-viniferin (3) and compound 8 were 40 microm. Although viniferin 
      significantly (p < 0.05) reduced pre-established in vitro biofilms and killed 
      bacteria within the biofilm, it was unable to prevent biofilm formation at 
      sub-MIC concentrations. The time kill experiment revealed that viniferin killed 
      bacteria and reduced 2.8 log(10) bacteria at 2 x MIC concentration after 24 h. 
      Scanning electron microscope (SEM) analysis and live/dead biofilm staining of 
      pre-established biofilms revealed that viniferin treatment disrupts membrane 
      integrity of biofilm bacteria. Crystal violet absorption, total protein, and DNA 
      and RNA release revealed that viniferin alters bacterial cell permeability, 
      eventually killing bacteria.
FAU - Yadav, Mukesh Kumar
AU  - Yadav MK
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Guro 
      Hospital, Seoul, South Korea.
AD  - Institute for Medical Device Clinical Trials, Korea University College of 
      Medicine, Seoul, South Korea.
FAU - Mailar, Karabasappa
AU  - Mailar K
AD  - College of Pharmacy and Integrated Research Institute for Drug Development, 
      Dongguk University, Seoul, South Korea.
FAU - Nagarajappa Masagalli, Jagadeesh
AU  - Nagarajappa Masagalli J
AD  - College of Pharmacy and Integrated Research Institute for Drug Development, 
      Dongguk University, Seoul, South Korea.
FAU - Chae, Sung-Won
AU  - Chae SW
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Guro 
      Hospital, Seoul, South Korea.
AD  - Institute for Medical Device Clinical Trials, Korea University College of 
      Medicine, Seoul, South Korea.
AD  - College of Pharmacy and Integrated Research Institute for Drug Development, 
      Dongguk University, Seoul, South Korea.
FAU - Song, Jae-Jun
AU  - Song JJ
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Guro 
      Hospital, Seoul, South Korea.
FAU - Choi, Won Jun
AU  - Choi WJ
AD  - College of Pharmacy and Integrated Research Institute for Drug Development, 
      Dongguk University, Seoul, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20190814
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6702469
OTO - NOTNLM
OT  - Streptococcus pneumoniae
OT  - antibiofilm
OT  - antimicobacterial
OT  - cell membrane
OT  - epsilon-viniferin
EDAT- 2019/09/03 06:00
MHDA- 2019/09/03 06:01
PMCR- 2019/08/14
CRDT- 2019/09/03 06:00
PHST- 2019/03/19 00:00 [received]
PHST- 2019/07/15 00:00 [accepted]
PHST- 2019/09/03 06:00 [entrez]
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2019/09/03 06:01 [medline]
PHST- 2019/08/14 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00890 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Aug 14;10:890. doi: 10.3389/fphar.2019.00890. eCollection 
      2019.